• 1
    Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230238.
  • 2
    Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 13181330.
  • 3
    Moberg L, Johansson H, Lukinius A et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 20392045.
  • 4
    Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 20602069.
  • 5
    Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 21482157.
  • 6
    O’Connell PJ, Hawthorne WJ, Holmes-Walker DJ et al. Clinical islet transplantation in type 1 diabetes mellitus: Results of Australia's first trial. Med J Aust 2006; 184: 221225.
  • 7
    Grey ST, Tsuchida A, Hau H, Orthner, CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the response of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153: 36643672.
  • 8
    Bernard GR, Vincent J-L, Laterre P-F et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699709.
  • 9
    Contreras JL Eckstein C, Smyth CA et al. Activated protein C preserves functional islet mass after intraportal transplantation: A novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004; 53: 28042815.
  • 10
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 14981505.
  • 11
    Labinaz M, Madan M, O'Shea JO et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy [ESPRIT] Trial). Am J Cardiol 2002; 90: 585590.
  • 12
    Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880886.
  • 13
    Bennet W, Sundberg, B, Groth CG et al. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 19071914.
  • 14
    Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: Possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51: 17791784.
  • 15
    St Pierre J, Yang LY, Tamirisa K et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999; 19: 22632268.
  • 16
    Mohammed A, Mehrabani PA, Coombs R, Molesworth L, Favaloro EJ. The MDA-180 coagulation analyser: A laboratory evaluation. Pathology 1997; 29: 176183.
  • 17
    Favaloro EJ, Henniker, A, Facey D, Hertzberg M. Discrimination of von Willebrands disease (VWD) subtypes: Direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84: 541547.
  • 18
    Moberg L, Korsgren, O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 2005; 142: 125131.
  • 19
    Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 2013920145.
  • 20
    Theoret J-F, Bienvenu J-G, Kumar A, Merhi Y. P-Selectin antagonism with recombinant P-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298: 658664.
  • 21
    Johansson H, Goto M, Dufrane D et al. Low molecular weight dextran sulfate: A strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant 2006; 6: 305312.
  • 22
    Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135145.